- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03742193
Pulmonary Resectable Metastases of Osteosarcoma With Anti-angiogenics and CHemotherapy (PROACH)
October 29, 2023 updated by: Weibin Zhang, MD, PhD., Ruijin Hospital
A Phase II Study of Gemcitabine-docetaxel Chemotherapy With Anti-angiogenic Therapy for Pulmonary Resectable Metastases of Osteosarcoma
The aim of this study is to evaluate the efficacy and safety of Second-line chemotherapy combined with Apatinib for the patients with resectable pulmonary metastasis of osteosarcoma.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
After standard chemotherapy and surgery for the localized disease, pulmonary metastases of osteosarcoma occurs in up to 40% of cases and still remain challenging without satisfactory regimen.
Apatinib is a oral kinase inhibitor of receptor tyrosine targeting VEGFR2.
A pilot study indicated that Apatinib improved the PFS after multi-line chemotherapy failure, and might partly reversed chemo-refractory status for advanced osteosarcoma.
Thus, the investigators explored the efficacy of combining Apatinib with current available second-line chemotherapy compared to chemotherapy alone for treating first resectable pulmonary metastases of osteosarcoma following the failure of first-line chemotherapy and wide/radical-margin surgery.
Participants will receive 250 mg of apatinib twice daily combined with gemcitabine-docetaxel (GD) regimen before and after the surgical resection of the pulmonary metastases.
Osteosarcoma patients with pulmonary recurrence only at baseline will be recruited in the study.
The primary end point is progression-free survival rate (PFR) compared with historical control.
A12 month PFR of 30% or less is considered inactive, while a 12 month PFR of 50% or greater is regarded as of interest for additional development.
With a type I error rate of 5% and a power of 83%, the number of patients needed for this design is 43.
Study Type
Interventional
Enrollment (Estimated)
43
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200025
- Ruijin Hospital Shanghai Jiao Tong University School of Medicine
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
10 years to 50 years (Child, Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- age between 10 and 50 years;
- diagnosis of histologically confirmed high grade osteosarcoma;
- identification of pulmonary metastases without the existence of local recurrence(previous re-resection of local recurrence with wide margin is allowed).
- resectable pulmonary nodule(s), defined as nodule(s) that are removable by wedge resection/ segmentectomy/lobectomy without necessitating a pneumonectomy (e.g., nodules immediately adjacent to the main stem bronchus or main pulmonary vessels)
- prior treatment consisted of standard National Comprehensive Cancer Network (NCCN) guideline recommended first-line chemotherapy
- wide/radical-margin surgical resection of the primary tumor completed at least 4 weeks before enrollment.
- Eastern Cooperative Oncology Group(ECOG) performance status 0-2 with a life expectancy >3 months;
- adequate renal, hepatic, and hemopoietic function;
- normal or controlled blood pressure;
- no thoracic comorbidities with adequate pulmonary function eligible for thoracic surgery
Exclusion Criteria:
- previously exposed to GD chemotherapy or VEGFR2 Tyrosine-kinase inhibitors (TKIs);
- existence of local recurrence;
- have had other kinds of malignant tumors at the same time;
- cardiac insufficiency or arrhythmia;
- uncontrolled complications, such as diabetes mellitus and so on;
- coagulation disorders or Hemorrhagic diseases ;
- metastases considered unresectable or borderline resectable at baseline
- intolerable of thoracis surgery
- pleural or peritoneal effusion that needs to be handled by surgical treatment;
- combined with other infections or wounds
- wound dystrophy, poor soft-tissue around implantation or other wound complications risky of non-healing given angiogenesis inhibitor assessed by the investigators
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Apatinib + GD group
Apatinib + GD regimen.
For unilateral metastases,3 cycles before metastasectomy, and 4 cycles after.
For bilateral metastases, 3 cycles before first metastasectomy, 1 cycle inbetween, and then second metastasectomy followed by 4 cycles.
Apatinib monotherapy is then maintained until 1 year following complete resection.
|
Apatinib 250mg tablet by mouth, bid.
48 hrs break before and 96 hrs after the surgical resection of the pulmonary metastases.
Other Names:
One cycle: gemcitabine 900 mg/m^2 over 90 min on Day 1, and gemcitabine 900 mg/m^2 and docetaxel 75 mg/m^2 on Day 8. Every 21 days were eligible. 1~2 -week break before and 2-week break after the surgical resection of the pulmonary metastases is taken.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
12 months Progression-free survival rate(12mPFR)
Time Frame: 12 months from the recruitment of the study
|
The proportion of patients with progression-free survival at 12 months according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1).
A 12mPFR of 30% or less is considered inactive, while a 12mPFR of 50% or greater is regarded as of interest for additional development
|
12 months from the recruitment of the study
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival (OS)
Time Frame: Baseline until death, followed through study completion, an average of 2 years
|
calculated from the date of treatment start until last follow-up or death, whichever comes first.
|
Baseline until death, followed through study completion, an average of 2 years
|
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Time Frame: through study completion, an average of 1 years
|
The occurrence of each adverse events(AEs), severe AEs(SAEs) and death according the CTCAE_5.0
|
through study completion, an average of 1 years
|
Progression free survival (PFS)
Time Frame: Baseline until disease progression or death, whichever occurs first (followed through study completion, an average of 1.5 years)
|
Progression free survival according to RECIST 1.1
|
Baseline until disease progression or death, whichever occurs first (followed through study completion, an average of 1.5 years)
|
OS rate
Time Frame: 12 and 24 months from baseline
|
the proportion of OS at 12, 24 months
|
12 and 24 months from baseline
|
Total resectability
Time Frame: after neoadjuvant systemic therapy, an average of 8~9 weeks
|
The number of patients undergoing pre-planned metastasectomy divided by the number of patients considered resectable at baseline
|
after neoadjuvant systemic therapy, an average of 8~9 weeks
|
Objective response rate (ORR)
Time Frame: after neoadjuvant systemic therapy, an average of 8~9 weeks
|
Complete Response(CR)+Partial Response(PR) after neoadjuvant systemic therapy
|
after neoadjuvant systemic therapy, an average of 8~9 weeks
|
Clinical benefit rate (CBR)
Time Frame: after neoadjuvant systemic therapy, an average of 8~9 weeks
|
CR+PR+stable disease (SD) after neoadjuvant systemic therapy
|
after neoadjuvant systemic therapy, an average of 8~9 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Exploratory outcome: Subgroup analysis of progression-free survival(PFS)
Time Frame: Baseline until disease progression or death, whichever occurs first (followed through study completion, an average of 1.5 years)
|
The PFS for each subgroups in terms of clinicopathological characteristics (age, gender, histological type, solitary or multiple metastases, unilateral or bilateral metastases, early or late metastases, calcifying or non-calcifying lesions, with or without lesion cavitation, with or without AEs [especially pneumothorax, hand-foot skin reactions, hair depigmentation], etc)
|
Baseline until disease progression or death, whichever occurs first (followed through study completion, an average of 1.5 years)
|
Exploratory outcome: The correlation of potential pathological biomarker with PFS
Time Frame: Baseline until disease progression or death, whichever occurs first (followed through study completion, an average of 1.5 years)
|
The correlation between the expression of VEGFR2, CD34, Ki-67 and immune cell infiltration by immunohistochemistry and PFS
|
Baseline until disease progression or death, whichever occurs first (followed through study completion, an average of 1.5 years)
|
Exploratory outcome: Tumor response pre-metastasectomy as a predictor of PFS
Time Frame: Baseline until disease progression or death, whichever occurs first (followed through study completion, an average of 1.5 years)
|
to compare the PFS of the three group according to tumor response pre-metastasectomy (group1: CR/PR, group2: SD, group3 PD)
|
Baseline until disease progression or death, whichever occurs first (followed through study completion, an average of 1.5 years)
|
Exploratory outcome: Tumor cavitation as a prognostic factor for oncological outcome
Time Frame: Baseline until disease progression or death, whichever occurs first (followed through study completion, an average of 1.5 years)
|
to compare the predictive value of the Crabb's modified RECIST criteria with the original RECIST 1.1 criteria in terms of PFS and OS
|
Baseline until disease progression or death, whichever occurs first (followed through study completion, an average of 1.5 years)
|
Exploratory outcome: AEs of the targeted therapy as prognostic factors for oncological outcome, especially pulmonary lesion cavitation/pneumothorax and hair depigmentation
Time Frame: Baseline until disease progression or death, whichever occurs first (followed through study completion, an average of 1.5 years)
|
to correlate the incidence of targeted therapy related AEs (especially pneumothorax, hand foot skin reactions, skin and hair depigmentation and fatigue)with the PFS/OS for the treatment arm.
|
Baseline until disease progression or death, whichever occurs first (followed through study completion, an average of 1.5 years)
|
Correlation of KDR 604 polymorphism with pulmonary lesion cavitation/pneumothorax and with PFS
Time Frame: Baseline until disease progression or death, whichever occurs first (followed through study completion, an average of 1.5 years)
|
According to our previous retrospective analysis, we aim the validate the correlation of KDR 604 AA,AG,GG genotype with the incidence of pulmonary lesion cavitation/pneumothorax and PFS among all patients.
|
Baseline until disease progression or death, whichever occurs first (followed through study completion, an average of 1.5 years)
|
Exploratory outcome: 1.0-mm CT scan for the early identification small lung nodule as pulmonary recurrence
Time Frame: Baseline until disease progression or death, whichever occurs first (followed through study completion, an average of 1.5 years)
|
to compare the diagnostic value of the 1.0 mm versus 5.0 mm CT scan for the radiological evaluation of small lung nodule as tumor recurrence
|
Baseline until disease progression or death, whichever occurs first (followed through study completion, an average of 1.5 years)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Weibin Zhang, PhD, MD, Ruijin Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 11, 2019
Primary Completion (Estimated)
November 15, 2023
Study Completion (Estimated)
December 30, 2023
Study Registration Dates
First Submitted
September 25, 2018
First Submitted That Met QC Criteria
November 14, 2018
First Posted (Actual)
November 15, 2018
Study Record Updates
Last Update Posted (Actual)
November 1, 2023
Last Update Submitted That Met QC Criteria
October 29, 2023
Last Verified
October 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms, Connective and Soft Tissue
- Neoplasms by Histologic Type
- Neoplasms
- Neoplastic Processes
- Neoplasms, Bone Tissue
- Neoplasms, Connective Tissue
- Sarcoma
- Neoplasm Metastasis
- Osteosarcoma
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Apatinib
Other Study ID Numbers
- 2018LLS-NO.84-3
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
The data of IPD is available to researcher's upon reasonable request, in accordance to the local legislator's policy ( such as genetic sequencing data)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Metastases
-
The First Affiliated Hospital of Guangzhou Medical...UnknownPulmonary Metastases | NSCLCChina
-
Azienda Sanitaria-Universitaria Integrata di UdineMaastricht UniversityUnknown
-
Masonic Cancer Center, University of MinnesotaWithdrawnPulmonary Metastases | Metastatic Melanoma | Brain Metastases | Hepatic MetastasesUnited States
-
University of PittsburghRITA Medical SystemsSuspendedPulmonary Metastases | NSCLCUnited States
-
Royal Marsden NHS Foundation TrustImperial College London; Royal Brompton & Harefield NHS Foundation Trust; Institute... and other collaboratorsRecruitingLung Cancer | Lung Metastases | Indeterminate Pulmonary Nodules | Second Primary CancerUnited Kingdom
-
Karolinska University HospitalKarolinska InstitutetActive, not recruiting
-
Zhejiang Cancer HospitalSecond Affiliated Hospital, School of Medicine, Zhejiang University; First... and other collaboratorsUnknownHepatocellular Carcinoma | Pulmonary Metastasis
-
Memorial Sloan Kettering Cancer CenterCompletedLung Metastases | Endobronchial Metastases | Pleural Metastases | Mediastinal MetastasesUnited States
-
Maria Sklodowska-Curie National Research Institute...RecruitingSoft Tissue Sarcoma | Pulmonary MetastasisPoland
-
Institut BergoniéGroupement Interrégional de Recherche Clinique et d'InnovationCompletedNeoplastic Cells, Circulating | Colo-rectal Cancer | Circulating Tumor Cell | Pulmonary Metastasis | Immune Evasion, TumorFrance
Clinical Trials on Apatinib
-
Elevar TherapeuticsCompletedAdenoid Cystic CarcinomaUnited States, Korea, Republic of
-
Shanghai Jiao Tong University Affiliated Sixth...UnknownSoft Tissue Sarcoma
-
Tianjin Medical University Cancer Institute and...Unknown
-
Peking University Cancer Hospital & InstituteRecruiting
-
Wuhan Union Hospital, ChinaWithdrawnColorectal Cancer | Chemotherapy | Angiogenesis
-
Tianjin Medical University Second HospitalJiangsu HengRui Medicine Co., Ltd.Unknown
-
Lei LiCompletedChemotherapy | Recurrent Cervical Carcinoma | Apatinib | Targeted Therapy | Persistent Advanced Cervical Carcinoma | Vascular Endothelial Growth Factor 2 InhibitorChina
-
The First Affiliated Hospital of Zhengzhou UniversityRecruitingEsophageal Cancer by AJCC V8 StageChina
-
Peking UniversityJiangsu HengRui Medicine Co., Ltd.Recruiting